Cd45.1 a20

Manufactured by Cytek Biosciences

CD45.1 (A20) is a monoclonal antibody used to identify and quantify cells expressing the CD45.1 antigen. It is commonly used in flow cytometry applications to detect and analyze specific cell populations.

Automatically generated - may contain errors

Lab products found in correlation

2 protocols using cd45.1 a20

Multi-parameter analysis of splenic and kidney cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Single cell suspension from spleen and kidney was incubated with FcR blocker (clone 2.4G2, generated in the lab). Cells were typically stained with fluorescence labeled streptavidin (Thermo Fisher), CD8β (H35-17.2, eBioscience), CD162 (2PH1, BD), CD45.1 (A20, Tonbo), CD45.2 (104, Tonbo) and the following antibodies from BioLegend, CD127 (A7R34), KLRG1 (2F1/KLRG1), CD69 (H1.2F3), CD103 (2E7), CD90.1 (OX-7), CD43 (1B11), CXCR3 (CXCR3-173), mouse P-selectin/hIgG1 Fc chimera protein and mouse E-selectin/hIgG1 Fc chimera protein. For E/P-selectin binding experiments, fluorescence labeled anti-human IgG secondary antibody was purchased from Jackson ImmunoResearch. In some experiments, Fixable Viability Dye eFluor 506 (eBioscience) was used to identify live cells. Washed and fixed samples were analyzed by BD LSRII or BD FACSCelesta and analyzed by FlowJO (TreeStar) software.

Ma C., Mishra S., Demel E.L., Liu Y, & Zhang N. (2016). TGF-β controls the formation of kidney-resident T cells via promoting effector T cell extravasation. Journal of immunology (Baltimore, Md. : 1950), 198(2), 749-756.

+ Open protocol

+ Expand

Comprehensive Immune Cell Phenotyping

Check if the same lab product or an alternative is used in the 5 most similar protocols

The following antibodies were used from BioLegend: B220 (RA3-6B2; 103225), Siglec H (551; 129608), MHC-II (M5/114.15.2; 107636), XCR1 (ZET; 148204 and 148216), CD24 (M1/69; 138508), CD40 (3/23; 124612), CD326 (G8.8; 118227), CD8 (53-6.7; 100751), Streptavidin BV650 (405231), Streptavidin BV711(405241), CD27 (LG.3A10; 124209), CD137 (17B5; 106105), CD45.2 (104; 109814), MHC-I (AF6-88.5; 116523), 7-AAD (420403), CD137L (TKS-1; 107105), CD44 (IM7; 103028), CD62L (MEL-14; 104420), CD3 (145-2C11; 100306), CD19 (MB19-1; 101504), Ter119 (Ter119; 116204), CD11b (M1/70; 101204), CD4 (GK1.5; 100412). The following antibodies were used from BD Biosciences: CD127 (SB/199; 562959), Ly6C (AL-21; 557359), Ly6G (1A8; 567599). The following antibodies were used from eBioscience/Invitrogen: CD11c (N418; 47-0114-82), Sirpα (P84; 46-1721-82), F4/80 (BM8; 12-4801-82), CD70 (FR70; 12-0701-82), TCRβ (T cell receptor β chain) (H57-597; 25-5961-82), Va2 (B20.1; 12-5812-82), CD105 (MJ7/18; 13-1051-82). The following antibody was used from Tonbo: CD45.1 (A20; 35-0453-U100). The following antibody was used from Cell Signaling Technology: Bcl-xL (54H6; 2764 S). The following antibodies were used from BioXCell: CD8β (Lyt 3.2; BE0223), CD40 (FGK4.5; BE0016-2).

Wu R., Ohara R.A., Jo S., Liu T.T., Ferris S.T., Ou F., Kim S., Theisen D.J., Anderson DA I.I.I., Wong B.W., Gershon T., Schreiber R.D., Murphy T.L, & Murphy K.M. (2022). Mechanisms of CD40-dependent cDC1 licensing beyond costimulation. Nature immunology, 23(11), 1536-1550.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!